Ultime notizie per Grupo Posadas (OTC:GPSAF) Azioni

Grupo Posadas SAB de CV is a Mexico-based company engaged in the hospitality industry. Its principal activities include construction, purchase, leasing, promotion, franchising, operation and management of hotels. The company's operating segment includes Hotel operation; Vacation Club; Hotel management, brand and other and Sale of non-strategic properties. It generates maximum revenue from the Hotel operation segment.

Grupo Posadas SAB de CV

It was reported on November 22, that AVI GOLDIN, CFO at Genie Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNE#NYSE">GNE</a>) executed a significant insider sell, according to an SEC filing.
What Happened: After conducting a thorough analysis, GOLDIN sold 7,300 shares of Genie Energy. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001528356/000095017024129977//Archives/edgar/data/1528356/000095017024129977/0000950170-24-129977-index.htm">U.S. Securities and Exchange Commission</a> on Friday. The total transaction value is $112,551.
Tracking the Friday's morning session, Genie Energy shares are trading at $15.9, showing a down of 0.0%.
<h3>Discovering Genie Energy: A Closer Look</h3>
Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.
<h3>Genie Energy: Financial Performance Dissected</h3>
Revenue Challenges: Genie Energy's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -10.5%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Utilities sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 33.87%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Genie Energy's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.38.
</li>
</ul>
Debt Management: Genie Energy's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Genie Energy's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 198.75.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 1.0, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 43.27, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001528356">Check Out The Full List Of Genie Energy's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Insider Trades

Trading Ideas

Massive Insider Trade At Genie Energy

New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) is gearing up to announce its quarterly earnings on Monday, 2024-11-25. Here's a quick overview of what investors should know before the release.
Analysts are estimating that New Jersey Resources will report an earnings per share (EPS) of $0.88.
The market awaits New Jersey Resources's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company missed EPS by $0.08, leading to a 2.0% increase in the share price the following trading session.
Here's a look at New Jersey Resources's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.01</td>
<td>1.32</td>
<td>0.75</td>
<td>0.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.09</td>
<td>1.41</td>
<td>0.74</td>
<td>0.30</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732287683_0.png" alt="eps graph" />
<h3>Tracking New Jersey Resources's Stock Performance</h3>
Shares of New Jersey Resources were trading at $49.85 as of November 21. Over the last 52-week period, shares are up 18.98%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Observations about New Jersey Resources</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on New Jersey Resources.
A total of 2 analyst ratings have been received for New Jersey Resources, with the consensus rating being Neutral. The average one-year price target stands at $49.0, suggesting a potential 1.71% downside.
<h3>Analyzing Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of UGI, ONE Gas and Southwest Gas Hldgs, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus outlook from analysts is an Neutral trajectory for UGI, with an average 1-year price target of $27.0, indicating a potential 45.84% downside.</li>
<li>As per analysts' assessments, ONE Gas is favoring an Outperform trajectory, with an average 1-year price target of $78.0, suggesting a potential 56.47% upside.</li>
<li>Southwest Gas Hldgs received a Neutral consensus from analysts, with an average 1-year price target of $78.0, implying a potential 56.47% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary presents essential metrics for UGI, ONE Gas and Southwest Gas Hldgs, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Jersey Resources</td>
<td>Neutral</td>
<td>4.38%</td>
<td>$55.19M</td>
<td>-0.54%</td>
</tr>
<tr>
<td>UGI</td>
<td>Neutral</td>
<td>-16.82%</td>
<td>$741M</td>
<td>-1.03%</td>
</tr>
<tr>
<td>ONE Gas</td>
<td>Outperform</td>
<td>1.36%</td>
<td>$150.02M</td>
<td>0.68%</td>
</tr>
<tr>
<td>Southwest Gas Hldgs</td>
<td>Neutral</td>
<td>-7.72%</td>
<td>$191.13M</td>
<td>0.01%</td>
</tr>
</tbody>
</table>

Key Takeaway:
New Jersey Resources ranks in the middle among its peers for revenue growth. It is at the bottom for gross profit and return on equity.
<h3>Unveiling the Story Behind New Jersey Resources</h3>
New Jersey Resources is an energy services holding company with regulated and nonregulated operations. Its regulated utility, New Jersey Natural Gas, delivers natural gas to nearly 600,000 customers in the state. NJR's nonregulated businesses include solar investments primarily in New Jersey and investments in several large midstream natural gas projects.
<h3>Understanding the Numbers: New Jersey Resources's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: New Jersey Resources's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 4.38%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Utilities sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: New Jersey Resources's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -4.2%, the company may face hurdles in effective cost management.
Return on Equity (ROE): New Jersey Resources's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.54% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): New Jersey Resources's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.17%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.59, caution is advised due to increased financial risk.
<a href="https://www.benzinga.com/quote/NJR/earnings">To track all earnings releases for New Jersey Resources visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

New Jersey Resources's Earnings: A Preview

A large exercise of company stock options by James Tarangelo, SVP and CFO at Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>) was disclosed in a new SEC filing on November 21, as part of an insider exercise.
What Happened: Tarangelo, SVP and CFO at Aramark, exercised stock options for 8,365 shares of ARMK stock. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001584509/000158450924000226//Archives/edgar/data/1584509/000158450924000226/0001584509-24-000226-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The exercise price of the options was $20.67 per share.
As of Friday morning, Aramark shares are down by 4.85%, with a current price of $38.46. This implies that Tarangelo's 8,365 shares have a value of $148,813.
<h3>Discovering Aramark: A Closer Look</h3>
Aramark provides food, facilities, and uniform services to a variety of clients and institutions. The majority of company revenue comes from its North American food and support services segment. Smaller but substantial segments include food and support services international, food and support services united states and uniform and career apparel. The food and support services segments provide food for school districts; colleges; healthcare facilities; correctional institutions; and business, sports, and entertainment venues. The uniform segment rents, delivers, cleans, and maintains work clothes and ancillary items like towels and mats to customers in North America and Japan. The company has hundreds of service locations and distribution centers across the United States and Canada.
<h3>A Deep Dive into Aramark's Financials</h3>
Positive Revenue Trend: Examining Aramark's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.16% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 8.99%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Aramark exhibits below-average bottom-line performance with a current EPS of 0.46.
</li>
</ul>
Debt Management: Aramark's debt-to-equity ratio is below the industry average. With a ratio of 1.83, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 40.83 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.62 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 13.05 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001584509">Check Out The Full List Of Aramark's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARMK

Options Movement At Aramark: James Tarangelo Exercises Worth $148K

On November 21, it was revealed in an SEC filing that David W Smith, VP at Carlisle Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) executed a significant exercise of company stock options.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000790051/000079005124000200//Archives/edgar/data/790051/000079005124000200/0000790051-24-000200-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that Smith, VP at Carlisle Companies, a company in the Industrials sector, just exercised stock options worth 275 shares of CSL stock with an exercise price of $150.0.
Carlisle Companies shares are trading, exhibiting up of 0.2% and priced at $442.41 during Friday's morning. This values Smith's 275 shares at $80,412.
<h3>Delving into Carlisle Companies's Background</h3>
Carlisle Companies Inc is a holding company. The company manufactures and sells single-ply roofing products and warranted systems and accessories for the commercial building industry. The company is organized into two segments including Carlisle Construction Materials and Carlisle Weatherproofing Technologies. The company's product portfolio includes moisture protection products, protective roofing underlayments, integrated air and vapor barriers, spray polyurethane foam and coating systems, and others. The majority of the company's revenue comes from the Carlisle Construction Materials segment, and more than half of the total revenue is earned in the United States.
<h3>Carlisle Companies: Delving into Financials</h3>
Revenue Growth: Carlisle Companies displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 5.86%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 38.57%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Carlisle Companies's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 5.31.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.83.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 23.69 is lower than the industry average, implying a discounted valuation for Carlisle Companies's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 4.22 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Carlisle Companies's EV/EBITDA ratio at 14.94 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000790051">Check Out The Full List Of Carlisle Companies's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options Movement At Carlisle Companies: David W Smith Exercises Worth $80K

Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) is gearing up to announce its quarterly earnings on Monday, 2024-11-25. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Pennant Park Investment will report an earnings per share (EPS) of $0.22.
The market awaits Pennant Park Investment's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.01, which was followed by a 1.03% increase in the share price the next day.
Here's a look at Pennant Park Investment's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.23</td>
<td>0.24</td>
<td>0.23</td>
<td>0.22</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.24</td>
<td>0.22</td>
<td>0.24</td>
<td>0.24</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>2.0%</td>
<td>-1.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732287675_0.png" alt="eps graph" />
<h3>Pennant Park Investment Share Price Analysis</h3>
Shares of Pennant Park Investment were trading at $6.94 as of November 21. Over the last 52-week period, shares are up 7.73%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analysts' Take on Pennant Park Investment</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Pennant Park Investment.
The consensus rating for Pennant Park Investment is Neutral, based on 1 analyst ratings. With an average one-year price target of $6.0, there's a potential 13.54% downside.
<h3>Peer Ratings Comparison</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of and Bridge Investment Group, three key industry players, offering insights into their relative performance expectations and market positioning.
<h3>Summary of Peers Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for and Bridge Investment Group, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bridge Investment Group</td>
<td>Outperform</td>
<td>-4.48%</td>
<td>$41.07M</td>
<td>5.58%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Pennant Park Investment ranks in the middle for Consensus rating among its peers. It is at the bottom for Revenue Growth. It is at the top for Gross Profit. It is at the bottom for Return on Equity.
<h3>Discovering Pennant Park Investment: A Closer Look</h3>
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.
<h3>Financial Milestones: Pennant Park Investment's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Pennant Park Investment faced challenges, resulting in a decline of approximately -76.81% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Pennant Park Investment's net margin excels beyond industry benchmarks, reaching 62.84%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Pennant Park Investment's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 0.75%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Pennant Park Investment's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.29%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Pennant Park Investment's debt-to-equity ratio stands notably higher than the industry average, reaching 1.54. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<a href="https://www.benzinga.com/quote/PNNT/earnings">To track all earnings releases for Pennant Park Investment visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PNNT

Pennant Park Investment's Earnings: A Preview

A substantial insider activity was disclosed on November 21, as Oliver, Chairman &amp; CEO at Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>), reported the exercise of a large sell of company stock options.
What Happened: A notable Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0000833444/000112760224027855//Archives/edgar/data/833444/000112760224027855/0001127602-24-027855-index.htm">U.S. Securities and Exchange Commission</a> revealed that Oliver, Chairman &amp; CEO at Johnson Controls Intl, exercised stock options for 293,534 shares of JCI, resulting in a transaction value of $14,433,066.
Currently, Johnson Controls Intl shares are trading down 0.0%, priced at $83.99 during Friday's morning. This values Oliver's 293,534 shares at $14,433,066.
<h3>All You Need to Know About Johnson Controls Intl</h3>
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration units, and fire and security solutions. Commercial HVAC accounts for over 45% of sales, fire and security represents roughly 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 15% of revenue. In fiscal 2023, Johnson Controls generated nearly $27 billion in revenue.
<h3>Understanding the Numbers: Johnson Controls Intl's Finances</h3>
Revenue Growth: Johnson Controls Intl's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 19.8%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: With a high gross margin of 48.36%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Johnson Controls Intl's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.95.
</li>
</ul>
Debt Management: Johnson Controls Intl's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.59.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 40.38 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 2.47, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Johnson Controls Intl's EV/EBITDA ratio, surpassing industry averages at 23.72, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>A Closer Look at Important Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000833444">Check Out The Full List Of Johnson Controls Intl's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

At Johnson Controls Intl, George Oliver Chooses To Exercise Options, Resulting In $14.43M

Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) reached a <a href="https://www.benzinga.com/money/solana-price-prediction">new all-time high on Friday</a> morning, trading at $264.31 on Coinbase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), according to TradingView.
This comes two years after the collapse of the <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/39012343/sol-down-3-as-ftx-bankruptcy-estate-concludes-solana-token-sales">crypto exchange FTX</a>, which had sent Solana prices plummeting.
What Happened: The token gained 18% over the past week, continuing its strong performance in 2024 with a 160% rise since the start of the year.
The collapse of Sam Bankman-Fried's FTX in late 2022 had pushed Solana to a cycle low of just under $10. 
However, the layer-1 blockchain has made a remarkable recovery, driven by several factors, including new exchange-traded fund (ETF) filings for Solana-based products. 
Recent filings from Bitwise, VanEck, 21Shares and Canary Capital to launch <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42011875/solana-ripple-litecoin-etfs-may-be-on-the-table-under-trump-administration-industry-experts-think">spot Solana ETFs</a> have added significant momentum to the asset.
Market analysts are optimistic about Solana's continued rise, setting a price target of $400 now that it has surpassed its previous all-time high of $260. 
SOL's popularity in the current cycle has been fueled by memecoin speculation, as its network provides a cost-effective and efficient platform for minting such tokens.
Beyond meme coins, <a href="https://www.benzinga.com/money/what-is-defi#:~:text=In%20simple%20terms%2C%20DeFi%20involves,is%20Decentralized%20Finance%20(DeFi)%3F">decentralized finance (DeFi) activity</a> on Solana has seen explosive growth.
The total value locked (TVL) on the Solana network has surged more than 500% in 2024, reaching $8.8 billion, according to DefiLlama. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42136031/charles-schwab-prepares-for-spot-cryptocurrency-trading-under-new-leadership">Charles Schwab Prepares For Spot Cryptocurrency Trading Under New Leadership</a>
Why It Matters: The broader cryptocurrency market has also played a pivotal role in Solana's rally.
Optimism about<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42122348/trumps-planned-crypto-council-may-oversee-bitcoin-reserve-report"> friendlier crypto regulations</a> under President-elect Donald Trump has driven overall market enthusiasm.
The total crypto market capitalization hit an all-time high of $3.42 trillion on November 22.
Additionally, the announcement of SEC Chair Gary Gensler's <a href="https://www.benzinga.com/government/regulations/24/11/42120607/gary-gensler-to-step-down-as-sec-chair-on-trumps-inauguration-day">resignation in January</a> has sparked further confidence in the altcoin market.
Gensler, known for his stringent stance on cryptocurrencies, had classified nearly all crypto assets other than Bitcoin as securities during his tenure.
His impending departure has fueled speculation about a more favorable regulatory environment for digital assets.
Solana is not the only altcoin benefiting from the current market momentum. XRP surged by 27% to $1.40 during early trading on Nov. 22, while Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>) and Avalanche (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/avax/usd">AVAX</a>) also posted double-digit gains, reflecting broad-based strength in the altcoin market.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42135905/bitcoin-nears-100000-momentum-could-continue-well-beyond-the-milestone-experts-note">Bitcoin Nears $100,000, &#8216;Momentum Could Continue Well Beyond The Milestone,&#8217; Experts Note</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$AVAX

$SOL

COIN

Solana Hits $264 Record High As ETF Filings, Regulatory Optimism Drive Market Momentum

Disclosed in a recent SEC filing on November 22, Mishra, EVP and COO at Innodata (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>), made a noteworthy transaction involving the exercise of company stock options.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000903651/000110465924121680//Archives/edgar/data/903651/000110465924121680/0001104659-24-121680-index.htm">U.S. Securities and Exchange Commission</a> on Friday revealed that Mishra, EVP and COO at Innodata in the Industrials sector, exercised stock options for 86,492 shares of INOD stock. The exercise price of the options was $1.21 per share.
The Friday morning market activity shows Innodata shares up by 2.47%, trading at $47.37. This implies a total value of $3,992,812 for Mishra's 86,492 shares.
<h3>About Innodata</h3>
Innodata Inc is a digital services and solutions company. It provides technology and services to information products and online retail destinations. The company has three operating segments: Digital data solutions, Synodex, and Agility. It serves publishers, media and information companies, digital retailers, banks, insurance companies, government agencies, and other industries. Geographically, it operates in the United States, United Kingdom, Netherlands, Canada, and Europe.
<h3>Unraveling the Financial Story of Innodata</h3>
Revenue Growth: Innodata's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 135.57%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 40.85%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Innodata's EPS reflects a decline, falling below the industry average with a current EPS of 0.6.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.1, Innodata adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 75.79 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 10.82 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 64.35 positions the company as being more valued compared to industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000903651">Check Out The Full List Of Innodata's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INOD

Options Exercise: Ashok Mishra At Innodata Realizes $3.99M

Whales with a lot of money to spend have taken a noticeably bearish stance on Booking Holdings.
Looking at options history for Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) we detected 31 trades.
If we consider the specifics of each trade, it is accurate to state that 29% of the investors opened trades with bullish expectations and 64% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $285,901 and 24, calls, for a total amount of $2,263,422.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $4000.0 and $5800.0 for Booking Holdings, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Booking Holdings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Booking Holdings's significant trades, within a strike price range of $4000.0 to $5800.0, over the past month.
<h3>Booking Holdings Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732287665_0_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$1618.6</td>
<td>$1593.6</td>
<td>$1615.0</td>
<td>$4300.00</td>
<td>$807.5K</td>
<td align="right">8</td>
<td align="right">5</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1143.9</td>
<td>$1107.0</td>
<td>$1129.16</td>
<td>$4300.00</td>
<td>$225.8K</td>
<td align="right">18</td>
<td align="right">2</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1394.7</td>
<td>$1380.1</td>
<td>$1380.1</td>
<td>$4000.00</td>
<td>$138.0K</td>
<td align="right">51</td>
<td align="right">1</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$66.5</td>
<td>$56.1</td>
<td>$60.63</td>
<td>$5350.00</td>
<td>$121.2K</td>
<td align="right">363</td>
<td align="right">94</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$321.1</td>
<td>$320.0</td>
<td>$320.0</td>
<td>$4950.00</td>
<td>$96.0K</td>
<td align="right">38</td>
<td align="right">3</td>
</tr>
</tbody>
</table>

<h3>About Booking Holdings</h3>
Booking is the world's largest online travel agency by sales, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates several branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
After a thorough review of the options trading surrounding Booking Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Booking Holdings's Current Market Status</h3>
<ul>
<li>With a volume of 10,693, the price of BKNG is down -0.29% at $5196.0. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 90 days.</li>
</ul>
<h3>Professional Analyst Ratings for Booking Holdings</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $5131.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Booking Holdings, which currently sits at a price target of $5250. 
&#x2A; Maintaining their stance, an analyst from Deutsche Bank continues to hold a Buy rating for Booking Holdings, targeting a price of $5200. 
&#x2A; Consistent in their evaluation, an analyst from DA Davidson keeps a Buy rating on Booking Holdings with a target price of $5005. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Booking Holdings, maintaining a target price of $5500. 
&#x2A; An analyst from Truist Securities persists with their Hold rating on Booking Holdings, maintaining a target price of $4700. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Booking Holdings, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

BKNG

A Closer Look at Booking Holdings's Options Market Dynamics

PennantPark Floating Rate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) is gearing up to announce its quarterly earnings on Monday, 2024-11-25. Here's a quick overview of what investors should know before the release.
Analysts are estimating that PennantPark Floating Rate will report an earnings per share (EPS) of $0.32.
The market awaits PennantPark Floating Rate's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS missed by $0.01, leading to a 0.37% increase in the share price on the subsequent day.
Here's a look at PennantPark Floating Rate's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.32</td>
<td>0.32</td>
<td>0.31</td>
<td>0.31</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.31</td>
<td>0.31</td>
<td>0.33</td>
<td>0.32</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732287665_0.png" alt="eps graph" />
<h3>PennantPark Floating Rate Share Price Analysis</h3>
Shares of PennantPark Floating Rate were trading at $11.04 as of November 21. Over the last 52-week period, shares are up 0.05%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/PFLT/earnings">To track all earnings releases for PennantPark Floating Rate visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PFLT

Preview: PennantPark Floating Rate's Earnings

In the last three months, 13 analysts have published ratings on Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $217.69, a high estimate of $298.00, and a low estimate of $167.00. Experiencing a 1.05% decline, the current average is now lower than the previous average price target of $220.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1732287660_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Texas Instruments is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$215.00</td>
<td>-</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$190.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>C J Muse</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$298.00</td>
<td>$268.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$167.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Tristan Gerra</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$230.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$240.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>C J Muse</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$210.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Texas Instruments. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Texas Instruments compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Texas Instruments's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Texas Instruments's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TXN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Texas Instruments analyst ratings.</a>
<h2>All You Need to Know About Texas Instruments</h2>
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
<h3>Understanding the Numbers: Texas Instruments's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Texas Instruments's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -8.41%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Texas Instruments's net margin excels beyond industry benchmarks, reaching 32.64%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Texas Instruments's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.86% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Texas Instruments's ROA excels beyond industry benchmarks, reaching 3.85%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.84, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 13 Analyst Ratings Have To Say About Texas Instruments

High-rolling investors have positioned themselves bearish on CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CRWD often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for CrowdStrike Holdings. This is not a typical pattern.
The sentiment among these major traders is split, with 22% bullish and 55% bearish. Among all the options we identified, there was one put, amounting to $61,500, and 8 calls, totaling $240,940.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $80.0 to $370.0 for CrowdStrike Holdings over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of CrowdStrike Holdings stands at 932.67, with a total volume reaching 124.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in CrowdStrike Holdings, situated within the strike price corridor from $80.0 to $370.0, throughout the last 30 days.
<h3>CrowdStrike Holdings Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732287660_0_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$21.05</td>
<td>$19.3</td>
<td>$20.5</td>
<td>$365.00</td>
<td>$61.5K</td>
<td>7</td>
<td align="right">38</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$87.15</td>
<td>$84.7</td>
<td>$86.5</td>
<td>$280.00</td>
<td>$34.6K</td>
<td>967</td>
<td align="right">4</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$26.3</td>
<td>$23.0</td>
<td>$23.0</td>
<td>$350.00</td>
<td>$34.5K</td>
<td>369</td>
<td align="right">0</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$21.4</td>
<td>$20.2</td>
<td>$20.84</td>
<td>$370.00</td>
<td>$31.2K</td>
<td>1.5K</td>
<td align="right">18</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$30.05</td>
<td>$29.7</td>
<td>$29.7</td>
<td>$350.00</td>
<td>$29.7K</td>
<td>2.7K</td>
<td align="right">41</td>
</tr>
</tbody>
</table>

<h3>About CrowdStrike Holdings</h3>
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.
Having examined the options trading patterns of CrowdStrike Holdings, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of CrowdStrike Holdings</h3>
<ul>
<li>Currently trading with a volume of 328,151, the CRWD's price is up by 1.61%, now at $363.32. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 4 days.</li>
</ul>
<h3>Professional Analyst Ratings for CrowdStrike Holdings</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $358.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Barclays persists with their Overweight rating on CrowdStrike Holdings, maintaining a target price of $372. 
&#x2A; In a cautious move, an analyst from CICC downgraded its rating to Market Perform, setting a price target of $295. 
&#x2A; An analyst from JMP Securities downgraded its action to Market Outperform with a price target of $400. 
&#x2A; An analyst from Cantor Fitzgerald persists with their Overweight rating on CrowdStrike Holdings, maintaining a target price of $370. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on CrowdStrike Holdings with a target price of $355. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for CrowdStrike Holdings, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

CRWD

Market Whales and Their Recent Bets on CRWD Options

Financial giants have made a conspicuous bearish move on Coinbase Glb. Our analysis of options history for Coinbase Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) revealed 13 unusual trades.
Delving into the details, we found 30% of traders were bullish, while 61% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $199,775, and 9 were calls, valued at $1,065,267.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $80.0 to $470.0 for Coinbase Glb over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Coinbase Glb's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Coinbase Glb's substantial trades, within a strike price spectrum from $80.0 to $470.0 over the preceding 30 days.
<h3>Coinbase Glb 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732287654_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$13.7</td>
<td>$13.1</td>
<td>$13.31</td>
<td>$300.00</td>
<td>$266.0K</td>
<td>3.1K</td>
<td>864</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$215.4</td>
<td>$212.7</td>
<td>$215.4</td>
<td>$80.00</td>
<td>$193.8K</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/29/24</td>
<td>$7.5</td>
<td>$7.0</td>
<td>$7.28</td>
<td>$320.00</td>
<td>$145.6K</td>
<td>1.9K</td>
<td>10.5K</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$86.05</td>
<td>$83.3</td>
<td>$83.74</td>
<td>$215.00</td>
<td>$125.6K</td>
<td>195</td>
<td>21</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$60.0</td>
<td>$57.95</td>
<td>$59.7</td>
<td>$250.00</td>
<td>$119.4K</td>
<td>74</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Coinbase Glb</h3>
Founded in 2012, Coinbase is the leading cryptocurrency exchange platform in the United States. The company intends to be the safe and regulation-compliant point of entry for retail investors and institutions into the cryptocurrency economy. Users can establish an account directly with the firm, instead of using an intermediary, and many choose to allow Coinbase to act as a custodian for their cryptocurrency, giving the company breadth beyond that of a traditional financial exchange. While the company still generates the majority of its revenue from transaction fees charged to its retail customers, Coinbase uses internal investment and acquisitions to expand into adjacent businesses, such as prime brokerage and data analytics.
Following our analysis of the options activities associated with Coinbase Glb, we pivot to a closer look at the company's own performance.
<h3>Current Position of Coinbase Glb</h3>
<ul>
<li>With a volume of 1,995,834, the price of COIN is up 0.17% at $295.74. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 83 days.</li>
</ul>
<h3>What Analysts Are Saying About Coinbase Glb</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $239.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Neutral rating for Coinbase Glb, targeting a price of $214. 
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Coinbase Glb, which currently sits at a price target of $204. 
&#x2A; Reflecting concerns, an analyst from Piper Sandler lowers its rating to Neutral with a new price target of $245. 
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Coinbase Glb with a target price of $290. 
&#x2A; An analyst from Monness, Crespi, Hardt downgraded its action to Buy with a price target of $245. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Coinbase Glb, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Looking At Coinbase Glb's Recent Unusual Options Activity

Throughout the last three months, 7 analysts have evaluated Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $89.71, a high estimate of $105.00, and a low estimate of $74.00. This upward trend is evident, with the current average reflecting a 5.54% increase from the previous average price target of $85.00.
<img src="https://www.benzinga.com/files/images/story/2024/1732287652_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Insmed's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Nicole Germino</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Nicole Germino</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Jason Zemansky</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Insmed. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insmed compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Insmed's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Insmed's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INSM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Insmed analyst ratings.</a>
<h2>About Insmed</h2>
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
<h3>A Deep Dive into Insmed's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Insmed's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.15% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Insmed's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -236.04%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -84.45%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Insmed's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -11.42%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 2.07.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INSM

Demystifying Insmed: Insights From 7 Analyst Reviews

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) is gearing up to announce its quarterly earnings on Monday, 2024-11-25. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Enanta Pharma will report an earnings per share (EPS) of $-1.16.
The announcement from Enanta Pharma is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.38, leading to a 1.17% increase in the share price the following trading session.
Here's a look at Enanta Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-10.0%</td>
<td>1.0%</td>
<td>12.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732287651_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Enanta Pharma were trading at $9.31 as of November 21. Over the last 52-week period, shares are down 1.98%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analyst Views on Enanta Pharma</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Enanta Pharma.
A total of 3 analyst ratings have been received for Enanta Pharma, with the consensus rating being Outperform. The average one-year price target stands at $23.67, suggesting a potential 154.24% upside.
<h3>Comparing Ratings with Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of and Macrogenics, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<h3>Overview of Peer Analysis</h3>
The peer analysis summary presents essential metrics for and Macrogenics, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macrogenics</td>
<td>Neutral</td>
<td>964.81%</td>
<td>$108.84M</td>
<td>63.31%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Enanta Pharma ranks in the middle among its peers for Consensus rating. It is at the top for Revenue Growth, indicating strong performance in this area. Enanta Pharma also leads in Gross Profit, showcasing efficient cost management. However, it falls behind in Return on Equity compared to its peers.
<h3>Delving into Enanta Pharma's Background</h3>
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
<h3>Financial Milestones: Enanta Pharma's Journey</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Decline in Revenue: Over the 3 months period, Enanta Pharma faced challenges, resulting in a decline of approximately -4.88% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Enanta Pharma's net margin excels beyond industry benchmarks, reaching -126.08%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Enanta Pharma's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -14.38%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -5.58%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Enanta Pharma's debt-to-equity ratio surpasses industry norms, standing at 0.34. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/ENTA/earnings">To track all earnings releases for Enanta Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENTA

Enanta Pharma's Earnings Outlook

Macro Economic Events

Econ #s

Economics

Michigan Consumer Expectations For November 76.9 Vs. 78.5 Est.; 78.5 Prior

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $11.0, with a high estimate of $11.00 and a low estimate of $11.00. This current average is unchanged from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1732287644_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Codexis among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Codexis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Codexis compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Codexis's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CDXS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Codexis analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Codexis: A Closer Look</h2>
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
<h3>Financial Insights: Codexis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Codexis's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 38.33%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -160.84%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Codexis's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -30.61%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Codexis's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -14.73%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.57, Codexis adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CDXS

Deep Dive Into Codexis Stock: Analyst Perspectives (4 Ratings)

In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and its primary competitors in the Broadline Retail industry. By closely examining key financial metrics, market position, and growth prospects, our aim is to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>Amazon.com Background</h3>
Amazon is the leading online retailer and marketplace for third party sellers. Retail related revenue represents approximately 75% of total, followed by Amazon Web Services' cloud computing, storage, database, and other offerings (15%), advertising services (5% to 10%), and other the remainder. International segments constitute 25% to 30% of Amazon's non-AWS sales, led by Germany, the United Kingdom, and Japan.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amazon.com Inc</td>
<td>42.39</td>
<td>8.05</td>
<td>3.42</td>
<td>6.19%</td>
<td>$32.08</td>
<td>$31.0</td>
<td>11.04%</td>
</tr>
<tr>
<td>Alibaba Group Holding Ltd</td>
<td>17.62</td>
<td>1.55</td>
<td>1.60</td>
<td>4.64%</td>
<td>$54.02</td>
<td>$92.47</td>
<td>5.21%</td>
</tr>
<tr>
<td>PDD Holdings Inc</td>
<td>11.22</td>
<td>4.12</td>
<td>3.24</td>
<td>13.54%</td>
<td>$37.97</td>
<td>$63.36</td>
<td>85.65%</td>
</tr>
<tr>
<td>MercadoLibre Inc</td>
<td>69.82</td>
<td>24.93</td>
<td>5.46</td>
<td>10.37%</td>
<td>$0.72</td>
<td>$2.44</td>
<td>35.27%</td>
</tr>
<tr>
<td>JD.com Inc</td>
<td>11.38</td>
<td>1.63</td>
<td>0.36</td>
<td>5.22%</td>
<td>$15.92</td>
<td>$45.04</td>
<td>5.12%</td>
</tr>
<tr>
<td>Coupang Inc</td>
<td>42.19</td>
<td>10.31</td>
<td>1.49</td>
<td>1.74%</td>
<td>$0.28</td>
<td>$2.27</td>
<td>27.2%</td>
</tr>
<tr>
<td>eBay Inc</td>
<td>15.47</td>
<td>5.43</td>
<td>3.05</td>
<td>11.59%</td>
<td>$0.95</td>
<td>$1.85</td>
<td>3.04%</td>
</tr>
<tr>
<td>Vipshop Holdings Ltd</td>
<td>6.43</td>
<td>1.33</td>
<td>0.48</td>
<td>2.76%</td>
<td>$1.47</td>
<td>$4.96</td>
<td>-9.18%</td>
</tr>
<tr>
<td>Dillard's Inc</td>
<td>11.19</td>
<td>3.51</td>
<td>1.05</td>
<td>6.37%</td>
<td>$0.15</td>
<td>$0.58</td>
<td>-4.19%</td>
</tr>
<tr>
<td>Ollie's Bargain Outlet Holdings Inc</td>
<td>27.67</td>
<td>3.50</td>
<td>2.53</td>
<td>3.14%</td>
<td>$0.08</td>
<td>$0.22</td>
<td>12.41%</td>
</tr>
<tr>
<td>MINISO Group Holding Ltd</td>
<td>17.10</td>
<td>3.97</td>
<td>2.79</td>
<td>6.26%</td>
<td>$0.79</td>
<td>$1.77</td>
<td>24.08%</td>
</tr>
<tr>
<td>Macy's Inc</td>
<td>23.18</td>
<td>0.97</td>
<td>0.18</td>
<td>3.53%</td>
<td>$0.44</td>
<td>$2.16</td>
<td>-3.48%</td>
</tr>
<tr>
<td>Nordstrom Inc</td>
<td>12.93</td>
<td>3.87</td>
<td>0.25</td>
<td>13.68%</td>
<td>$0.4</td>
<td>$1.49</td>
<td>3.23%</td>
</tr>
<tr>
<td>Kohl's Corp</td>
<td>6.43</td>
<td>0.48</td>
<td>0.11</td>
<td>1.73%</td>
<td>$0.35</td>
<td>$1.6</td>
<td>-4.18%</td>
</tr>
<tr>
<td>Savers Value Village Inc</td>
<td>18.83</td>
<td>3.20</td>
<td>0.95</td>
<td>5.09%</td>
<td>$0.07</td>
<td>$0.22</td>
<td>0.53%</td>
</tr>
<tr>
<td>Groupon Inc</td>
<td>13.33</td>
<td>9.15</td>
<td>0.68</td>
<td>34.72%</td>
<td>$0.03</td>
<td>$0.1</td>
<td>-9.48%</td>
</tr>
<tr>
<td>Average</td>
<td>20.32</td>
<td>5.2</td>
<td>1.61</td>
<td>8.29%</td>
<td>$7.58</td>
<td>$14.7</td>
<td>11.42%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>By closely examining Amazon.com, we can identify the following trends: 
<ul>
<li>
Notably, the current Price to Earnings ratio for this stock, 42.39, is 2.09x above the industry norm, reflecting a higher valuation relative to the industry.
</li>
<li>
With a Price to Book ratio of 8.05, which is 1.55x the industry average, Amazon.com might be considered overvalued in terms of its book value, as it is trading at a higher multiple compared to its industry peers.
</li>
<li>
The Price to Sales ratio of 3.42, which is 2.12x the industry average, suggests the stock could potentially be overvalued in relation to its sales performance compared to its peers.
</li>
<li>
The company has a lower Return on Equity (ROE) of 6.19%, which is 2.1% below the industry average. This indicates potential inefficiency in utilizing equity to generate profits, which could be attributed to various factors.
</li>
<li>
The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $32.08 Billion is 4.23x above the industry average, highlighting stronger profitability and robust cash flow generation.
</li>
<li>
The company has higher gross profit of $31.0 Billion, which indicates 2.11x above the industry average, indicating stronger profitability and higher earnings from its core operations.
</li>
<li>
The company's revenue growth of 11.04% is significantly lower compared to the industry average of 11.42%. This indicates a potential fall in the company's sales performance.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732287643_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio is an important measure to assess the financial structure and risk profile of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When evaluating Amazon.com alongside its top 4 peers in terms of the Debt-to-Equity ratio, the following insights arise:
<ul>
<li>
Compared to its top 4 peers, Amazon.com has a stronger financial position indicated by its lower debt-to-equity ratio of 0.52.
</li>
<li>
This suggests that the company relies less on debt financing and has a more favorable balance between debt and equity, which can be seen as a positive attribute by investors.
</li>
</ul>
<h3>Key Takeaways</h3>
For Amazon.com, the PE, PB, and PS ratios are all high compared to its peers in the Broadline Retail industry, indicating overvaluation. The low ROE suggests lower profitability relative to its high EBITDA and gross profit margins. Additionally, the low revenue growth implies a slower expansion rate compared to industry peers.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMZN

Investigating Amazon.com's Standing In Broadline Retail Industry Compared To Competitors

Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) is gearing up to announce its quarterly earnings on Monday, 2024-11-25. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Bath &amp; Body Works will report an earnings per share (EPS) of $0.47.
Anticipation surrounds Bath &amp; Body Works's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.01, leading to a 4.0% drop in the share price on the subsequent day.
Here's a look at Bath &amp; Body Works's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.36</td>
<td>0.32</td>
<td>1.87</td>
<td>0.35</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.37</td>
<td>0.38</td>
<td>2.06</td>
<td>0.48</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>5.0%</td>
<td>-0.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732287638_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Bath &amp; Body Works were trading at $30.55 as of November 21. Over the last 52-week period, shares are up 2.21%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BBWI/earnings">To track all earnings releases for Bath &amp; Body Works visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBWI

Earnings Preview: Bath & Body Works

Stifel analyst Brad Reback maintains Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Buy and lowers the price target from $795 to $725.

Comments

Grupo Posadas

Notizie

Ultime notizie per Grupo Posadas (OTC:GPSAF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO